HER2 in Colorectal Carcinoma
- 1 September 2020
- journal article
- review article
- Published by Elsevier in Surgical Pathology Clinics
- Vol. 13 (3) , 485-502
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2Proceedings of the National Academy of Sciences, 2012
- Comprehensive molecular characterization of human colon and rectal cancerNature, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody CetuximabScience Translational Medicine, 2011
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialThe Lancet, 2010
- A phase I trial of paclitaxel and trastuzumab in combination with interleukin-12 in patients with HER2/neu-expressing malignanciesMolecular Cancer Therapeutics, 2009
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic targetAnnals of Oncology, 2008
- Assessment of a HER2 scoring system for gastric cancer: results from a validation studyHistopathology, 2008
- A genetic model for colorectal tumorigenesisCell, 1990